scholarly journals The fiscal value of human lives lost from Novel Coronavirus (2019-nCoV) in China

2020 ◽  
Author(s):  
Joses M. Kirigia ◽  
Rosenabi Deborah Karimi Muthuri
Keyword(s):  
Human Capital ◽  
Life Expectancy ◽  
Economic Model ◽  
Discount Rates ◽  
Female Life Expectancy ◽  
Specific Objective ◽  
The World ◽  
Japanese Female ◽  
National Life ◽  
Novel Coronavirus

Abstract Objective: According to the WHO novel coronavirus (2019-nCoV) situation report 16, as at 5 th February 2020, there was a total of 24363 confirmed 2019-nCoV cases in China. That consisted of the world 491. The specific objective of this study was to estimate, using human capital approach, the fiscal value of human lives lost due to 2019-nCoV in China as at 5 th February 2020. Results: The deaths from 2019-nCoV had a discounted (at 3%) total fiscal value of Int$174,895,675. Out of which, 63.2% was borne by people aged 25-49 years, 27.8% by people aged 50-64 years, and 9.0% by people aged 65 years and above. Average fiscal value per death was Int$ 356,203. Re-estimation of the economic model alternately with 5% and 10 discount rates led to a reduction in the expected total fiscal value by 21.3% and 50.4%, respectively. Furthermore, re-estimation of the economic model using the Japanese female life expectancy of 87.1 years (highest in the world), instead of the national life expectancy of 76.4 years, increased the total fiscal value by Int$ 43,415,455 (24.8%).

scholarly journals The fiscal value of human lives lost from coronavirus disease (COVID-19) in China

2020 ◽  
Author(s):  
Joses M. Kirigia ◽  
Rosenabi Deborah Karimi Muthuri
Keyword(s):  
Life Expectancy ◽  
Economic Model ◽  
Discount Rates ◽  
Average Life ◽  
Average Life Expectancy ◽  
Specific Objective ◽  
National Life

Abstract Objective: According to the WHO coronavirus disease (COVID-19) situation report 35, as of 24 th February 2020, there was a total of 77,262 confirmed COVID-19 cases in China. That included 2,595 deaths. The specific objective of this study was to estimate the fiscal value of human lives lost due to COVID-19 in China as of 24 th February 2020. Results: The deaths from COVID-19 had a discounted (at 3%) total fiscal value of Int$ 924,346,795 in China. Out of which, 63.2% was borne by people aged 25-49 years, 27.8% by people aged 50-64 years, and 9.0% by people aged 65 years and above. The average fiscal value per death was Int$ 356,203. Re-estimation of the economic model alternately with 5% and 10 discount rates led to a reduction in the expected total fiscal value by 21.3% and 50.4%, respectively. Furthermore, the re-estimation of the economic model using the world’s highest average life expectancy of 87.1 years (which is that of Japanese females), instead of the national life expectancy of 76.4 years, increased the total fiscal value by Int$ 229,456,430 (24.8%).

scholarly journals The net present value of human lives lost due to coronavirus disease (COVID-19) in the Islamic Republic of Iran

2020 ◽  
Author(s):  
Joses M. Kirigia ◽  
Rose Nabi Deborah Karimi Muthuri ◽  
Newton Gitonga Muthuri
Keyword(s):  
Life Expectancy ◽  
Economic Model ◽  
Net Present Value ◽  
Human Life ◽  
Discount Rates ◽  
Islamic Republic ◽  
Present Value ◽  
The World ◽  
Islamic Republic Of Iran

Abstract Objective As of 11 April 2020, there were 68,192 confirmed cases, including 4,232 deaths. This study aimed to estimate the net present value of human lives lost due to COVID-19 in Iran as of 11 April 2020.Results The 4,232 human lives lost had a total net present value of Int$ 436,275,007. The average net present value per human life was Int$103,090. Re-estimation of the economic model with 5% and 10% discount rates resulted in a reduction in the expected total net present value by Int$ 64,881,144 (14.9%) and Int$ 168,066,782 (38.5%), respectively. Additional re-calculation of the economic model using the highest life expectancy in the world (i.e., that of the Japanese Females) increased the total net present value of human lives lost by 114%.

How to Age Successfully

2021 ◽  
pp. 302-319
Author(s):  
Ozum Egilmez ◽  
Gozde Koca
Keyword(s):  
Human Capital ◽  
Life Expectancy ◽  
Successful Aging ◽  
Human Population ◽  
Human Capital Development ◽  
Societal Issue ◽  
The World ◽  
Capital Development

Successful aging is a multi-faceted term with continuous attention while the human population is aging around the globe. The aging components differ while the world is changing, such as an increase in life expectancy or dramatic affection of the general COVID-19 pandemic. As aging is investigated in many disciplines, this research's focus is interdisciplinary to be able to reveal the acknowledgment of the benefits of the potential aging country. Therefore, aging is to be determined as a societal issue in this research under the lenses of continuous engagement with life. To that, the authors use fuzzy BWM approach to reveal the relations of components adopted from the MacArthur model of successful aging. Findings revealed that human capital development was the best factor whilst the relevance of successful aging was the worst factor in adopting relevant policies for successfully aging.

scholarly journals The monetary value of human life losses associated with COVID-19 in Turkey

2020 ◽  
Vol 2 ◽  
pp. 44
Author(s):  
Joses Muthuri Kirigia ◽  
Rose Nabi Deborah Karimi Muthuri ◽  
Lenity Honesty Kainyu Nkanata
Keyword(s):  
Life Expectancy ◽  
Human Life ◽  
Age Groups ◽  
International Health ◽  
Years Of Life Lost ◽  
Age Group ◽  
Health Coverage ◽  
Discount Rates ◽  
Monetary Value ◽  
National Life

Background:  This study aimed to appraise the monetary value of human life losses associated with COVID-19 in Turkey. To our knowledge, it is the first study in Turkey to value human life losses associated with COVID-19.  Methods: A human capital approach (HCA) model was applied to estimate the total monetary value of the 4,807 human lives lost in Turkey (TMVHL) from COVID-19 by 15 June 2020. The TMVHL equals the sum of monetary values of human lives lost (MVHL) across nine age groups. The MVHL accruing to each age group is the sum of the product of discount factor, years of life lost, net GDP per capita, and the number of COVID-19 deaths in an age group. The HCA model was re-calculated five times assuming discount rates of 3%, 5%, and 10% with a national life expectancy of 78.45 years; and the world highest life expectancy of 87.1 years and global life expectancy of 72 years with 3% discount rate. Results: The 4807 human life losses from COVID-19 had a TMVHL of Int$1,098,469,122; and a mean of Int$228,514 per human life. Reanalysis with 5% and 10% discount rates, holding national life expectancy constant, reduced the TMVHL by Int$167,248,319 (15.2%) and Int$ 429,887,379 (39%), respectively. Application of the global life expectancy reduced the TMVHL by 36.4%, and use of world highest life expectancy increased TMVHL by 69%. However, the HCA captures only the economic production losses incurred as a result of years of life lost. It ignores non-market contributions to social welfare and the adverse effects of economic activities. Conclusions: Additional investment is needed to bridge the persisting gaps in International Health Regulations capacities, Universal Health Coverage, and safely managed water and sanitation services.

scholarly journals The discounted value of human lives lost due to COVID-19 in France

F1000Research ◽  
2020 ◽  
Vol 9 ◽  
pp. 1247 ◽  
Author(s):  
Joses Muthuri Kirigia ◽  
Rose Nabi Deborah Karimi Muthuri ◽  
Lenity Honesty Kainyu Nkanata ◽  
Newton Gitonga Muthuri
Keyword(s):  
Life Expectancy ◽  
Human Life ◽  
Economic Value ◽  
International Health ◽  
Discount Rates ◽  
Average Life ◽  
Average Life Expectancy ◽  
World Average ◽  
Life Expectancy At Birth ◽  
The World

Background: This study estimates the total discounted value of human lives lost (TDVHL) due to COVID-19 in France as of 14 September 2020. Methods: The human capital approach (HCA) model was used to estimate the TDVHL of the 30,916 human lives lost due to COVID-19 in France; i.e., assuming a discount rate of 3% and the national average life expectancy at birth of 83.13 years. To test the robustness of the estimated TDVHL, the model was rerun (a) using 5% and 10% discount rates, while holding the French average life expectancy constant; and (b) consecutively substituting national life expectancy with the world average life expectancy of 73.2 years and the world highest life expectancy of 88.17 years.  Results: The human lives lost had a TDVHL of Int$10,492,290,194, and an average value of Int$339,381 per human life lost. Rerun of the HCA model with 5% and 10% discount rates decreased TDVHL by Int$1,304,764,602 (12.4%) and Int$3,506,938,312 (33%), respectively. Re-calculation of the model with the world average life expectancy decreased the TDVHL by Int$7,750,187,267 (73.87%). Contrastingly, re-estimation of the model with the world’s highest life expectancy augmented TDVHL by Int$3,744,263,463 (35.7%). Conclusions: The average discounted economic value per human life lost due to COVID-19 of Int$339,381 is 8-fold the France gross domestic product per person. Such evidence constitutes an additional argument for health policy makers when making a case for increased investment to optimise France’s International Health Regulation capacities and coverage of essential health services, and safely managed water and sanitation services.

scholarly journals The Dollar Value of Human Life Losses Associated With COVID-19 in Canada

2021 ◽  
Author(s):  
Joses Muthuri Kirigia ◽  
Rose Nabi Deborah Karimi Muthuri
Keyword(s):  
Life Expectancy ◽  
Economic Model ◽  
Human Life ◽  
Premature Mortality ◽  
Discount Rates ◽  
Average Life ◽  
Economic Sectors ◽  
Average Life Expectancy ◽  
International Dollar ◽  
Total Dollar

Background: The coronavirus disease 2019 (COVID-19) pandemic continues to cause morbidity and premature mortality and ravage the socio-economic sectors in Canada.Objectives: The study aimed to appraise the Total Dollar Value of Human Life Losses (TDVHL) associated with COVID-19 in Canada. Methods: The net output approach was applied in the dollar valuation of the 8810 human life losses associated with COVID-19 in Canada as of July 16, 2020. The economic model wasrerun assuming 3%, 5%, and 10% discount rates with Canada’s life expectancy of 83 years, the world’s average life expectancy of 73 years, the world’s highest average life expectancy of88 years, and a 3% discount rate. Results: The human lives lost to COVID-19 had an estimated value of the international dollar (Int$) 2037021173 and an average of Int$ 231217 per human life lost. Quebec and Ontarioprovinces alone accounted for 94.99% of the TDVHL. Reanalysis of the economic model with discount rates of 5% and 10% resulted in declines in TDVHL of Int$ 192721390 (9%)and Int$ 530132423 (26%), respectively. Substitution of the nation with the word’s average life expectancy shrank the TDVHL by Int$ 1754972473 (86%) while applying the world’shighest life expectancy triggered a growth in the TDVHL of Int$ 498674987 (24%).

Comparative docking of SARS-CoV-2 receptors antagonists from repurposing drugs

2020 ◽  
Author(s):  
Micael Davi Lima de Oliveira ◽  
Kelson Mota Teixeira de Oliveira
Keyword(s):  
World Health Organisation ◽  
World Health ◽  
Lung Cells ◽  
The Novel ◽  
High Modulation ◽  
Main Protease ◽  
The World ◽  
Novel Coronavirus ◽  
Viral Receptors ◽  
Theoretical Results

According to the World Health Organisation, until 16 June, 2020, the number of confirmed and notified cases of COVID-19 has already exceeded 7.9 million with approximately 434 thousand deaths worldwide. This research aimed to find repurposing antagonists, that may inhibit the activity of the main protease (Mpro) of the SARS-CoV-2 virus, as well as partially modulate the ACE2 receptors largely found in lung cells, and reduce viral replication by inhibiting Nsp12 RNA polymerase. Docking molecular simulations were performed among a total of 60 structures, most of all, published in the literature against the novel coronavirus. The theoretical results indicated that, in comparative terms, paritaprevir, ivermectin, ledipasvir, and simeprevir, are among the most theoretical promising drugs in remission of symptoms from the disease. Furthermore, also corroborate indinavir to the high modulation in viral receptors. The second group of promising drugs includes remdesivir and azithromycin. The repurposing drugs HCQ and chloroquine were not effective in comparative terms to other drugs, as monotherapies, against SARS-CoV-2 infection.

Current updates on COVID-19 - A review

2020 ◽  
Vol 10 (1) ◽  
pp. 1-8
Author(s):  
Ghotekar D S ◽  
Vishal N Kushare ◽  
Sagar V Ghotekar
Keyword(s):  
World Health Organization ◽  
Common Cold ◽  
Respiratory Diseases ◽  
Gastrointestinal Diseases ◽  
Hubei Province ◽  
World Health ◽  
The World ◽  
The Common ◽  
Novel Coronavirus ◽  
Health Organization

Coronaviruses are a family of viruses that cause illness such as respiratory diseases or gastrointestinal diseases. Respiratory diseases can range from the common cold to more severe diseases. A novel coronavirus outbreak was first documented in Wuhan, Hubei Province, China in December 2019. The World Health Organization (WHO) has declared the coronavirus disease 2019 (COVID-19) a pandemic. A global coordinated effort is needed to stop the further spread of the virus. A novel coronavirus (nCoV) is a new strain that has not been identified in humans previously. Once scientists determine exactly what coronavirus it is, they give it a name (as in the case of COVID-19, the virus causing it is SARS-CoV-2).

An approach to the understanding of the clinical-etiopathological aspect of COVID-19 (SARS-CoV-2)

2020 ◽  
Vol 11 (SPL1) ◽  
pp. 862-869
Author(s):  
Meena Kumari ◽  
Monika Agrawal ◽  
Rakesh Kumar Singh ◽  
Parameswarappa S Byadgi
Keyword(s):  
World Health ◽  
Apical Surface ◽  
Therapy Assessment ◽  
Differentiated Cells ◽  
The World ◽  
Polarized Epithelia ◽  
Well Differentiated ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Epidemiological Characteristics

Currently, the world is facing a health and socioeconomic crisis caused by the novel coronavirus disease COVID-19. On 11 March 2020, the World Health Organization (WHO) has declared this disease as a pandemic. The condition (COVID-19) is an infectious disorder triggered by a newly discovered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2. Most of the COVID-19 infected patients will experience mild to moderate respiratory symptoms and recover without any unique therapy. Assessment of the clinical and epidemiological characteristics of SARS-CoV-2 cases suggests the infected patients will not be contagious until the onset of severe symptoms and affects the other organs. Well-differentiated cells of apical airway epithelia communicating with ACE2 were promptly infected to SARS-CoV-2 virus. But the expression of ACE 2 in poorly differentiated epithelia facilitated SARS spike (S) protein-pseudo typed virus entry and it is replicated in polarized epithelia and especially exited via the apical surface. Limiting the transmission of COVID-19 infection & its prevention can be regarded as a hierarchy of controls. In this article, we briefly discuss the most recent advances in respect to aetiology, pathogenesis and clinical progression of the disease COVID-19.

Sign in / Sign up

Export Citation Format

Share Document